Key Takeaways for CVS Health Stock
- CVS Health delivered revenue of $99.85 billion in Q1 2026, up 6% year-over-year.
- Operating income reached $4.12 billion in Q1 2026, up 25% year-over-year, with operating margins expanding to 4%.
- Gross profit surged 9% year-over-year to $15.05 billion, pushing gross margins to a multi-quarter high of 15%.
- TIKR’s model values CVS stock at around $128 by December 2030, implying roughly 26% total return from the current price of $102.
CVS Health Beat Q1 Estimates and Raised Its 2026 Guidance as Aetna Turned Around
CVS Health Corporation (CVS) posted $99.85 billion in revenue in Q1 2026, delivering a top-line beat and raising its full-year adjusted EPS guidance following May 6 earnings.
The standout development this quarter was a more than $1 billion year-over-year improvement in adjusted operating income at Aetna, which had weighed on results across the prior two years as elevated medical costs pressured the industry.
CFO Brian Newman made the trajectory explicit on the Q1 earnings call: “We drove over $1 billion of year-over-year AOI improvement at Aetna.”
The company raised full-year 2026 adjusted EPS guidance to a range of $7.30 to $7.50, up from the previous range of $7.00 to $7.20, and now expects total revenues of at least $405 billion for the year.
Management reaffirmed its target of reaching Aetna’s long-term margin objectives by 2028, with CEO David Joyner describing the company as being on a clear path: “Our revised outlook continues to reflect the core principles of our guidance philosophy: credible targets, disciplined execution and clear opportunities for outperformance.”
Looking ahead, CVS highlighted its Health100 platform, an AI-native consumer engagement tool set to launch later in 2026 that connects payers, PBMs, pharmacies, and providers on a single system.
The company also achieved a 200 basis point improvement in GLP-1 prescription share, driven by its CostVantage pricing model and expanded direct-to-consumer pharmacy access.
CVS Health’s Gross Profit Inflection Is Outrunning the Market’s Expectations
CVS posted gross profit of $15.05 billion in Q1 2026, the highest quarterly figure in at least eight quarters, representing 9% growth year-over-year.
Gross margins expanded to 15% in Q1 2026, the strongest reading in at least two years and a sharp recovery from the 12% trough reached in Q4 2025.
Total operating expenses held at $10.93 billion, essentially unchanged from the prior quarter’s $10.86 billion, a signal that cost discipline is intact as gross profit recovers.
The gap between gross profit growth and operating expense growth widened decisively in Q1 2026, with gross profit expanding faster than the cost base for the second consecutive quarter.
Operating income of $4.12 billion represented a 25% year-over-year increase, and operating margins reached 4%, the highest in the eight-quarter data series provided.
The prior-year period showed operating margins as low as 2% in Q2 2025, making the current recovery a meaningful inflection rather than a seasonal blip.
The operating leverage story here is straightforward: revenue grew 6%, gross profit grew 9%, and operating expenses grew by a fraction of either.
CVS Narrows the Operating Margin Gap on Humana While UnitedHealth Holds the Sector Lead
CVS Health posted a 4% operating margin in Q1 2026, its strongest reading in at least eight quarters, compared to Humana’s 0% in the same period as the rival insurer absorbed peak medical cost pressure.
UnitedHealth Group (UNH) sustained an 8% operating margin in the most recent quarter, maintaining a structural lead over both peers that has held consistently across the eight-quarter series.
The more instructive comparison is the CVS-versus-Humana (HUM) gap: CVS sat at negative 1% as recently as Q4 2025 before recovering to 4%, while Humana printed negative 2% in the same quarter and has not yet demonstrated a comparable inflection.
CVS’s margin trajectory from a trough of 1% in Q4 2025 to 4% in Q1 2026 is a larger sequential recovery than either peer achieved in the same window.
The UNH margin of 8% in Q1 2026 establishes the sector ceiling, and the 4-percentage-point gap between CVS and UnitedHealth represents both the remaining recovery runway and the valuation discount the market is still pricing in.
Is CVS Stock Undervalued in 2026? TIKR’s $128 Target Implies the Market Is Behind
TIKR’s model values CVS Health at approximately $128 by December 2030, implying around 26% total return from the current price of $102, or roughly 5% per year.
That target requires the gross margin recovery visible in Q1 2026 to persist, with operating leverage continuing to widen as revenue scales above the cost base.
The 15% gross margin posted in Q1 2026 is the clearest income statement argument for that trajectory, and the Q1 operating income print of $4.12 billion shows the business has already begun converting that improvement into bottom-line results.
Should You Invest in CVS Health Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS Health Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CVS stock on TIKR for Free →
Is CVS Health stock a buy right now?
CVS stock carries a consensus Buy rating from analysts and raised its 2026 adjusted EPS guidance to a range of $7.30 to $7.50 after Q1 results, suggesting the market is still catching up to improving fundamentals.
